Peptide Decoding
New?New to peptides?Start here →
Decoding

BGM0504_Dosage, benefits & legal status

The INN relsipatide and the development code BG128 are listed together in the FDA substance registry, and BG128 is the code BrightGene uses in its own patent filings. No nomenclature source checked here states that BGM0504 and BG128 are the same molecule; that link rests on four matching structural features and on a research reagent catalog.

Published November 11, 2026

Tirzepatide with one lysine added to the end and the fat chain moved onto it.

Weight loss and blood sugar controlGLP-1 and GIP dual receptor agonistInvestigational
InGLP-1 agonistsWeight loss
Dose5, 10 or 15 mg once weekly in phase 3
FrequencyOnce weekly
RouteUnder the skin, once weekly; an oral tablet is in phase 2
StatusInvestigational; marketing application accepted in China
MixYour choice, open the BGM0504 calculator
CycledWeekly and ongoing in trials, with no planned stop

See how this dose compares across the library →

01

What is BGM0504?

Plain language first. The technical label stays, but it never stands alone.

Overview

This is a Chinese-developed weekly injection that hits the same two gut hormone receptors as tirzepatide, the drug sold as Mounjaro and Zepbound. It is not approved anywhere, including China, though a Chinese filing for weight management was accepted for review in June 2026. The design is unusually easy to describe, because its developers published it: take tirzepatide's chain of 39 building blocks, add one lysine on the end to make 40, then move the fatty tail that makes the drug long-lasting off the middle of the chain and onto that new end position. In a completed phase 3 trial of 652 adults in China, the highest dose produced weight loss of around 19% over 52 weeks against roughly 3% on placebo. The company announced 19.3% in May 2026 and a conference presentation in October reported 19.2%. That is the kind of small drift worth noticing when a single number is doing the marketing. The more interesting unpublished result is the trial that pitted it directly against tirzepatide. That finished in January 2026 and nobody has released what it showed.

The technical version

BGM0504 is a synthetic dual GLP-1 and GIP receptor agonist from BrightGene Bio-Medical Technology, given under the skin once weekly and filed in China for long-term weight management after a completed phase 3 trial in 652 adults. Its developers describe its design in a peer-reviewed paper as tirzepatide with one lysine added at position 40, the fatty acid side chain relocated from lysine 20 to that new lysine 40, and the linker between peptide and lipid lengthened. It is approved nowhere. A marketing application for weight management was accepted by China's Center for Drug Evaluation in June 2026, starting a review rather than ending one. A head-to-head phase 2 trial against tirzepatide in obesity completed in January 2026 and its results are not public.

What it's used for

Under development for chronic weight management in adults with overweight or obesity, the indication filed in China, and for type 2 diabetes, where phase 3 trials against semaglutide are running in China and Indonesia. An oral tablet formulation is in phase 2. None of these is an approved use.

02

How does BGM0504 work?

What it does in the body, and where.

Tirzepatide works because it activates two gut hormone receptors at once and because a fatty acid chain keeps it in the blood for days. This molecule keeps the first part and rearranges the second.

  1. 01
    The peptide chain is tirzepatide's
    All 39 residues, including the two synthetic alpha-aminoisobutyric acid residues at positions 2 and 13 that protect it from being cut in half.
  2. 02
    One lysine is added at position 40
    A single residue on the end of the chain, and the only sequence change the developers' design paper describes.
  3. 03
    The fatty acid moves to that new lysine
    Relocated off lysine 20, leaving lysine 20's amino group free, with the linker between peptide and lipid lengthened at the same time.
  4. 04
    Both receptors are still activated
    GLP-1 and GIP, as tirzepatide does, with the long-acting hardware relocated to the chain's end.
Anatomical illustration highlighting metabolic organs
WHAT THIS COMPOUND ACTS ON:
GLP-1Fullness, slower stomachGIPInsulin after meals
03

What else is it used for?

Each group carries its own evidence level.

Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

The structure, measured against tirzepatide

Research only
  • Lab studyThe developers' design paper, published in July 2024 with BrightGene's chief executive as first author, states plainly that BGM0504 adds a lysine at position 40 on the basis of tirzepatide, moves the acylation from lysine 20 to lysine 40, extends the linker from a gamma-glutamyl plus two short glycol units to a gamma-glutamyl plus two three-unit glycol spacers, and preserves lysine 20's free amino group.
  • Lab studyCompared position by position against this site's tirzepatide sequence, the 40-residue chain in the FDA registry record for relsipatide is identical for its first 39 residues and adds a lysine at 40. The registry places the lipid on that lysine's side-chain nitrogen and lists the two three-unit glycol spacers the design paper describes.
  • No dataOne chemical detail disagrees. The design paper calls the fatty diacid C18 and says it is retained from tirzepatide; tirzepatide's is C20, and the registry record gives a 19-carboxy-nonadecyl chain, meaning C20. The paper appears to have mis-stated the chain length for both molecules rather than describing a genuine difference.
  • No dataThe registry's calculated molecular weight of 4028.5 for relsipatide should not be quoted as the drug's weight. The record carries its own validation warning that the lysine modification contributes nothing to the calculation because its fragment has no stored mass, so the figure is the bare peptide without the lipid and linker.

Phase 3 in weight management

Investigational
  • Human trial652 adults actually enrolled, Chinese, overweight or obese and without diabetes, randomized to 5, 10 or 15 mg weekly or placebo. Completed, with a primary completion date of March 17, 2026 and a record last updated October 15, 2026.
  • Human trialPrimary endpoints sit at week 36: percent change in body weight, and the proportion achieving at least 5% weight reduction. Week 52 results, including the proportions reaching 10%, 15% and 20% reduction, are secondary. The headline figure everyone quotes is a week 52 secondary result.
  • RegulatoryCompany topline, May 5, 2026: mean weight reduction up to 19.3% over 52 weeks against about 3% on placebo, with all primary and key secondary endpoints met.
  • Human trialConference presentation of the same trial, October 2, 2026: up to 19.2% at 52 weeks, with reported improvements in waist circumference, blood pressure, lipids, uric acid and glycemic markers. No adverse event table has been published either time.

Phase 2, including a head-to-head that has not been reported

Investigational
  • Human trialPhase 2 in obesity: 120 Chinese adults, three doses after a two to six week titration, then weekly for 24 weeks with a two-week follow-up. Placebo-adjusted weight reduction 10.77% to 19.78% and waist circumference 8.0 to 12.98 cm, presented at a diabetes meeting in June 2025.
  • Human trialPhase 2 in type 2 diabetes: 67 patients in China, three doses against both placebo and semaglutide, with change in HbA1c at week 12 as the primary endpoint. The developer reported better glucose control than semaglutide.
  • No dataAn open-label phase 2 trial comparing BGM0504 directly with tirzepatide in adults with obesity completed on January 14, 2026. Its record was updated in October 2026 and no results have been released. This is the single most informative study in the program and it is the one nobody has seen.

The rest of the program

Investigational
  • Human trialType 2 diabetes phase 3 against semaglutide added to metformin, 537 participants estimated in China, plus a separate phase 3 against semaglutide in Indonesia with primary completion estimated April 30, 2027.
  • Human trialBRIGHT-1, a phase 3 against semaglutide in early type 2 diabetes with obesity, recruiting since September 17, 2026, with diabetes remission among its questions and primary completion estimated September 2028.
  • human-earlyAn oral tablet: phase 1 completed March 5, 2026, and a phase 2 trial testing tablets against placebo over 20 weeks in overweight or obese adults without diabetes.
  • human-earlyA drug interaction study of gastric emptying with metformin and warfarin, and a bioequivalence study of the injection, both completed. The developer states the compound has been studied in more than 1,000 patients and that a US phase 1 bridging study is complete.
Often left out

Setting 19.2% against tirzepatide's SURMOUNT figures as though the two were compared. They were not. This trial's comparator was placebo, in a Chinese population, with primary endpoints at week 36 rather than the 72 weeks tirzepatide's obesity trial ran. The actual head-to-head against tirzepatide completed in January 2026 and has not been reported. The second error is calling the drug approved in China: a marketing application was accepted for review in June 2026. That is a filing, not an approval. The third is the alias. Relsipatide and BG128 are tied to each other in the FDA substance registry, and BG128 is the code in BrightGene's own patents, but no nomenclature source checked here states that BGM0504 is that molecule.

The published record

Research index

4

Papers about BGM0504 · this compound only

Searched: BGM0504, BGM-0504, relsipatide, BG128.

Left out: tirzepatide (THE critical rejection, and the deepest one in this batch. This molecule IS tirzepatide's 39 residues plus one lysine, by its own developers' published account. Tirzepatide is on this site with SURMOUNT and SURPASS data, a US label, a boxed warning and a 72-week obesity trial. A query that catches both will import all of it onto a compound approved nowhere. Note also that BrightGene's own patents code tirzepatide as BG121, one digit from this drug's own BG128); Mounjaro (tirzepatide's diabetes brand name); Zepbound (tirzepatide's obesity brand name, and the comparison every piece of coverage makes); semaglutide (the ACTIVE COMPARATOR in three of this drug's phase 3 trials and its phase 2 diabetes trial. On this site with its own vast literature. A combination search returns semaglutide's trials, not this drug's); GIP receptor agonist (the mechanism term, shared with twelve existing cards); dual agonist (the class term, shared with far more); BrightGene (the developer, which also has BGM1812, an amylin analog with its own preclinical data presented at the same meeting, plus a generics and peptide manufacturing business); BGM1812 (that amylin analog specifically. Presented alongside this drug and easily merged into it); BRIGHT-1 (the newest phase 3's acronym, which collides with unrelated trials); Aib (alpha-aminoisobutyric acid, the synthetic residue at positions 2 and 13, shared with tirzepatide and several other analogs); Ji Linong (the investigator who presented the phase 3 at EASD 2026, with a large independent publication record).

4 papers tagged human · 4 not reviews or lab · 3 clinical trial publications

Furthest stage reached: Published trials only, 3 clinical trial publications, no phased trial registered

Compare this against the whole library →

Browse the records
In animals1
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

BGM0504 vial rendering
Compound field notes

At a glance

Four things to know about BGM0504

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

Long enough for weekly dosing; no published figure

04

How much, and do you cycle it?

The range, and whether you take breaks.

5, 10 or 15 mg once weekly in phase 3, once weekly. Weekly and ongoing in trials, with no planned stop Trial dose

Weight regain after stopping is the pattern for every drug in this class, and the phase 3 ran 52 weeks of continuous weekly dosing with endpoints at weeks 36 and 52.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Long enough for weekly dosing; no published figureNo figure

No half-life figure for BGM0504 appears in the sources checked here. The weekly interval and the fatty acid and linker chemistry that produce it are documented in the developers' design paper; the pharmacokinetic parameters are not.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: 5 up to 15 mgTrial dose

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
Full calculator with reorder date →Read a syringe →
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

BGM0504 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 20% charged residues, 48% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Any expectation of access: approved nowhere, and available only inside a trial
  • Reading the 19.2% or 19.3% figure as a head-to-head result against tirzepatide when it is not
  • Treating the June 2026 Chinese filing acceptance as an approval when it is not

Stop and get help

These are emergencies. Seek care.
  • Not applicable outside a trial, where the protocol and the investigator govern
  • Severe or persistent abdominal pain with vomiting would be the presentation to report immediately in any trial of this drug class

Common effects

Expected, and usually mild.
  • Gastrointestinal effects of the class, expected but not quantified in any published phase 3 table
  • Reductions in waist circumference alongside weight, reported in phase 2 as 8.0 to 12.98 cm placebo-adjusted across three doses
  • Improvements in blood pressure, lipids, uric acid and glycemic markers, reported in general terms for the phase 3 without figures

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is BGM0504 approved?

And where the numbers on this page come from.

No. BGM0504 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

What has happened recently

Approved in no country. The phase 3 weight-management trial is NCT06704581, also registered in China as CTR20243983 and run as study BGM0504-III-WL, with 652 participants actually enrolled and a primary completion date of March 17, 2026. Topline results were announced May 5, 2026 and presented as a late-breaking oral presentation at the European Association for the Study of Diabetes meeting on October 2, 2026. A new drug application for long-term weight management was accepted by the Center for Drug Evaluation of China's National Medical Products Administration in June 2026. Acceptance starts the review. A phase 1 bridging study has been completed in the United States, and the developer has said it is seeking a Western partner ahead of a global trial.

You can compare this against the whole library, or read how to check a seller.

10

What else is like BGM0504?

Others in GLP-1 agonists, side by side.

If you're weighing BGM0504, it's worth reading BI 3034701, Bofanglutide (GZR18), and Brenipatide (LY3537031) in the same class.

YOU ARE HERE
BGM0504

Tirzepatide with one lysine added to the end and the fat chain moved onto it.

Investigational
Dose
5, 10 or 15 mg once weekly in phase 3
How often
Once weekly
BI-3034701
BI 3034701

The drug that shows 'triple agonist' is a shape, not a mechanism.

Investigational
Dose
No human dose disclosed; six dose groups are being tested
How often
Not disclosed
GZR18
Bofanglutide (GZR18)

Semaglutide with two small changes, tested as an injection every two weeks. Its China phase 3 met its main goal in 2026, the company reports; in a US phase 2 it trailed tirzepatide.

Investigational
Dose
24 or 48 mg every two weeks, after a step-up from 3 mg (phase 3 trials)
How often
Every two weeks
BRENIPATIDE
Brenipatide (LY3537031)

A GLP-1 drug being developed for addiction and depression, not obesity.

Investigational
Dose
No established dose
How often
Not established
See every GLP-1 drug side by side
See how this compares to 14 other GLP-1 drugs

Guides for this compound

Sources

Beyond these, 4 records are indexed for this compound. Browse the records